LGD-6972 is primarily researched for its potential in managing type 2 diabetes. It functions as a glucagon receptor antagonist, which helps in reducing blood sugar levels by inhibiting the action of glucagon, a hormone that increases glucose production in the liver. This makes it a promising candidate for improving glycemic control in patients who struggle with traditional treatments. Additionally, its mechanism of action may offer benefits in weight management, as it can potentially reduce appetite and promote weight loss, which is often a challenge for individuals with type 2 diabetes. Ongoing studies aim to further explore its efficacy and safety in clinical settings.